Altimmune (ALT) Revenue & Revenue Breakdown
Altimmune Revenue Highlights
Latest Revenue (Y)
$20.00K
Latest Revenue (Q)
$5.00K
Main Segment (Y)
Grant
Altimmune Revenue by Period
Altimmune Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $20.00K | -95.31% |
| 2023-12-31 | $426.00K | -726.47% |
| 2022-12-31 | $-68.00K | -101.54% |
| 2021-12-31 | $4.41M | -46.12% |
| 2020-12-31 | $8.19M | 41.09% |
| 2019-12-31 | $5.80M | -43.85% |
| 2018-12-31 | $10.33M | 24792.58% |
| 2017-12-31 | $41.50K | -99.21% |
| 2016-12-31 | $5.23M | -50.85% |
| 2015-12-31 | $10.64M | 4.42% |
| 2014-12-31 | $10.19M | -43.11% |
| 2013-12-31 | $17.91M | -28.85% |
| 2012-12-31 | $25.18M | 3.75% |
| 2011-12-31 | $24.27M | 15.59% |
| 2010-12-31 | $20.99M | -23.80% |
| 2009-12-31 | $27.55M | -16.29% |
| 2008-12-31 | $32.91M | 124.75% |
| 2007-12-31 | $14.64M | 692.53% |
| 2006-12-31 | $1.85M | 215.27% |
| 2005-12-31 | $586.07K | - |
Altimmune generated $20.00K in revenue during NA 2024, up -95.31% compared to the previous quarter, and up 0.34% compared to the same period a year ago.
Altimmune Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $5.00K | - |
| 2024-06-30 | $5.00K | - |
| 2024-03-31 | $5.00K | -86.49% |
| 2023-12-31 | $37.00K | -89.78% |
| 2023-09-30 | $362.00K | 5933.33% |
| 2023-06-30 | $6.00K | -71.43% |
| 2023-03-31 | $21.00K | -119.09% |
| 2022-12-31 | $-110.00K | -5600.00% |
| 2022-09-30 | $2.00K | -75.00% |
| 2022-06-30 | $8.00K | -75.00% |
| 2022-03-31 | $32.00K | -99.02% |
| 2021-12-31 | $3.28M | 1980.27% |
| 2021-09-30 | $157.56K | 14.49% |
| 2021-06-30 | $137.62K | -83.57% |
| 2021-03-31 | $837.52K | -63.79% |
| 2020-12-31 | $2.31M | -21.28% |
| 2020-09-30 | $2.94M | 307.13% |
| 2020-06-30 | $721.64K | -67.39% |
| 2020-03-31 | $2.21M | 284.28% |
| 2019-12-31 | $575.80K | -10.59% |
| 2019-09-30 | $643.98K | -60.40% |
| 2019-06-30 | $1.63M | -44.98% |
| 2019-03-31 | $2.96M | 14.17% |
| 2018-12-31 | $2.59M | -1.74% |
| 2018-09-30 | $2.63M | 8.99% |
| 2018-06-30 | $2.42M | 48849.78% |
| 2018-03-31 | $4.94K | -99.82% |
| 2017-12-31 | $2.81M | -38.83% |
| 2017-09-30 | $4.59M | 92891.90% |
| 2017-06-30 | $4.94K | -99.39% |
| 2017-03-31 | $804.07K | -28.17% |
| 2016-12-31 | $1.12M | 12.63% |
| 2016-09-30 | $993.88K | -52.92% |
| 2016-06-30 | $2.11M | 109.93% |
| 2016-03-31 | $1.01M | -20.59% |
| 2015-12-31 | $1.27M | 9.57% |
| 2015-09-30 | $1.16M | 0.55% |
| 2015-06-30 | $1.15M | -83.74% |
| 2015-03-31 | $7.07M | 287.05% |
| 2014-12-31 | $1.83M | 89.75% |
| 2014-09-30 | $962.45K | -73.70% |
| 2014-06-30 | $3.66M | -2.23% |
| 2014-03-31 | $3.74M | 2.42% |
| 2013-12-31 | $3.65M | 4.75% |
| 2013-09-30 | $3.49M | -18.79% |
| 2013-06-30 | $4.30M | -33.66% |
| 2013-03-31 | $6.48M | 7.67% |
| 2012-12-31 | $6.01M | -10.19% |
| 2012-09-30 | $6.70M | 6.00% |
| 2012-06-30 | $6.32M | 2.73% |
| 2012-03-31 | $6.15M | -1.45% |
| 2011-12-31 | $6.24M | 18.62% |
| 2011-09-30 | $5.26M | -18.18% |
| 2011-06-30 | $6.43M | 1.44% |
| 2011-03-31 | $6.34M | -7.53% |
| 2010-12-31 | $6.85M | 9.78% |
| 2010-09-30 | $6.24M | 30.63% |
| 2010-06-30 | $4.78M | 53.36% |
| 2010-03-31 | $3.12M | -56.27% |
| 2009-12-31 | $7.13M | - |
Altimmune generated $5.00K in revenue during Q3 2024, up 0.00% compared to the previous quarter, and up 83.33% compared to the same period a year ago.
Altimmune Revenue Breakdown
Altimmune Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 | Dec 20 | Dec 18 |
|---|---|---|---|
| Grant | $3.70M | $3.10M | $10.31M |
| License And Service | - | - | $19.78K |
Latest
Altimmune's latest annual revenue breakdown by segment (product or service), as of Dec 21: Grant (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|
| Grant | $3.30M | $100.00K | $100.00K | $200.00K | $2.58M | $2.63M | $2.41M |
| License And Service | - | - | - | - | $4.95K | - | - |
| License and Service | - | - | - | - | - | $4.95K | $4.95K |
Latest
Altimmune's latest quarterly revenue breakdown by segment (product or service), as of Dec 21: Grant (100.00%).
Altimmune Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals | $957.80M | $250.40M |
| ARDX | Ardelyx | $333.62M | $98.24M |
| MDGL | Madrigal Pharmaceuticals | $180.13M | $62.17M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
| FBIO | Fortress Biotech | $55.13M | $14.63M |
| VSTM | Verastem | $10.00M | $10.00M |
| XFOR | X4 Pharmaceuticals | $2.56M | $560.00K |
| ALT | Altimmune | $20.00K | $5.00K |
| INMB | INmune Bio | $14.00K | - |
| AKRO | Akero Therapeutics | - | - |
| AVXL | Anavex Life Sciences | - | - |
| CABA | Cabaletta Bio | - | - |
| VKTX | Viking Therapeutics | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| ZURA | Zura Bio | - | - |
| CGTX | Cognition Therapeutics | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| BIVI | BioVie | - | - |
| ATHA | Athira Pharma | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| HOOK | HOOKIPA Pharma | - | $4.70M |
| SAVA | Cassava Sciences | - | - |